口服去氧氟尿苷化疗联合放疗治疗局部晚期鼻咽癌的临床研究  

Clinical Study of Doxifluridine Plus Concurrent Radiotherapy in Locally Advanced Nasopharyngeal Carcinoma

作　　者：徐新颜[1] 温莹浩[1] 汤江林 

机构地区：[1]江西省萍乡市人民医院,江西萍乡337000

出　　处：《中国医学创新》2013年第28期8-10,共3页Medical Innovation of China

基　　金：萍乡市2010年市级指导性计划项目(萍科字[2010]55号)

摘　　要：目的：探讨去氧氟尿苷单药用于局部晚期鼻咽癌同步放化疗的有效性和安全性。方法：90例局部晚期鼻咽癌患者,随机分为去氧氟尿苷单药组、PF方案组和单纯放疗组,每组各30例。去氧氟尿苷单药组接受去氧氟尿苷单药同步放化疗（去氧氟尿苷胶囊口服,每日剂量0.8~1.2 g,分3次口服,从放疗开始当日至放疗结束当日）;单纯放疗组接受单纯放疗;PF方案组接受PF方案同步放化疗（5-Fu500 mg/m2静滴dl-5,DDP 80 mg/m2静滴d1,21 d为1周期）。观察各组疗效及不良反应。结果：去氧氟尿苷单药组与PF方案组疗效相当,均优于单独放疗组。在不良反应方面,去氧氟尿苷单药组的恶心呕吐、口腔黏膜炎、白细胞减少等不良反应的发生率均低于PF方案组,比较差异均有统计学意义（P〈0.05）。结论：去氧氟尿苷单药用于局部晚期鼻咽癌同步放化疗疗效好,不良反应轻,患者耐受性好。Objective： To investigate the effect and safety of doxifluridine combined with concurrent radiotherapy for locally advanced nasopharyngeal carcinoma.Method： Total of 90 patients with locally advanced nasopharyngeal carcinoma were randomly divided into the doxifluridine single drug group, the PF regimen group and the simple radiotherapy group, 30 cases in each group.The doxifluridine single drug group was given chemotherapy of single doxifluridine （ doxifluridine capsule 0.8-1.2 g/d PO, from the first day to the last day of radiotherapy ） with concurrent radiotherapy. The simple radiotherapy group was given single radiotherapy.The PF regimen group was given chemotherapy of PF regimen jointing concurrent radiotherapy （ 5-FU 500mg/m2 iv d1-d5, cisplatin 80 mg/m2 iv dl ; 21days was a cycle ） .The therapeutic effect and side effect of all groups were evaluated.Result： The effect of doxifluridine single drug group was similar to that of the PF regimen group and better than that of single radiotherapy group.The incidence of nausea/vomiting, oral mucositis and leucopenia in simple radiotherapy group were lower than that in PF regimen group.Conclusion： Chemotherapy of single doxifluridine with concurrent radiotherapy is an effective and well-tolerated regimen for the treatment of locally advanced nasopharyngeal carcinoma.

关 键 词：去氧氟尿苷 局部晚期鼻咽癌 同步放化疗 

分 类 号：R739.63[医药卫生—肿瘤]